Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: A randomized multicentric comparison to pamidronate

Supportive Care in Cancer

Volumn 11, Issue 8, 2003, Pages 539-547

  Pecherstorfer, M ^a   Steinhauer, E U ^b   Rizzoli, R ^c   Wetterwald, M ^d   Bergstrom B ^e  

^a First Dept of Med/Medical Oncology   (Austria)

^b KLINIKUM KASSEL   (Germany)

^c Hôpital Cantonal   (Switzerland)

^d CENTRE HOSPITALIER   (France)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

Bisphosphonate; Hypercalcemia; Ibandronate; Malignancy; Pamidronate

Indexed keywords

CALCIUM; IBANDRONIC ACID; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; HEART ARREST; HUMAN; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; ILEUS; INFUSION; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEPSIS; THROMBOCYTOPENIA; THROMBOSIS; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; HUMANS; HYPERCALCEMIA; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 0041733424     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-003-0477-1     Document Type: Article

References (21)

1. Body JJ, Lichinitser MR, Diehl IJ, et al (1999) Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Eur J Cancer 35:575a (abstract 2222)
2. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F (1983) Renal failure associated with intravenous diphosphonates. Lancet 1:471
3. Diel IJ, Lichinitser MR, Body JJ, Schlosser K, Moecks J, Cavalli F, Dornoff W, Gorbunova VA, McClockey E, Weiss J, Kanis JA (1999) Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate. Eur J Cancer 35; S83 (abstract 269)
4. Francis MD, Slough CL (1984) Acute intravenous infusion of disodium dihydrogen (1-hydroxyethylidene) diphosphonate: mechanism of toxicity. J Pharm Sci 73:1097-1110
5. Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R, et al (1992) Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10:134-142
6. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384-392
7. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19(2): 558-567
8. Mundy GR (1990) Calcium homeostasis: hypercalcemia and hypocalcemia. Martin Dunitz, London, pp 69-100
9. Neugebauer G, Koehler W, Akinkunmi L (2001) Influence of peak ibandronic acid concentrations after 6 mg iv administration with shortened infusion time (15 and 30 minutes) on renal safety in man. Proc Am Soc Clin Oncol 20:122a (abstract 486)
10. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297-304
11. Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, Ogris E (1993) Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 34:1039-1044
12. Pecherstorfer M, Schilling T, Blind E, Zimmer-Roth I, Baumgartner G, Ziegler R, Raue F (1994) Parathyroid hormone-related protein and life expectancy in hyperealcemic cancer patients. J Clin Endocrinol Metab 78:1268-1270
13. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thurlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiebaud D (1996) Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268-276
14. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ (1996) Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 11:587-593
15. Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer-Roth I, Thiebaud D (2000) Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 15:147-154
16. Pocock SJ (1979) Allocation of patients to treatment in clinical trials. Biometrics 35:183-197
17. Portale AA (1990) Blood calcium, phosphorus and magnesium. In Favus MJ (ed): Primer on the metabolic bone diseases and disorders of mineral metabolism. William Byrd, Richmond, pp 62-64
18. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990) Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients, Ann Intern Med 112:499-504
19. Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thurlimann B, Walls J, Lichinitser MR, Rizzoll R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ (1997) Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 75:295-300
20. Thiébaud D, Jaeger P, Jacquet AF, Burckhardt P (1988) Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 6:762-768
21. Zojer N, Keck AV, Pecherstorfer M (1999) Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21:389-406